(SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas
This is a prospective study to document the local control rates with SBRT specifically for pulmonary metastases from soft tissue sarcoma. This study will prospectively document acute and late toxicity, quality of life (QoL), tumor control, and survival.
Checked against the public recordLast updated Feb 28, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Medical College of Wisconsin
- Interventions being studied
- Radiation: SBRT
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * ≥18 years of age * Pathologic confirmation of primary soft tissue sarcoma with pathologic or radiographic evidence of pulmonary metastatic disease * No evidence of extra pulmonary progression of disease for 3 months prior to enrollment on study * 1-5 pulmonary lesions all ≤5 cm in size * Medically inoperable or declines surgery * Patients may have had previous treatment for pulmonary metastases Exclusion Criteria: * Patients who have uncontrolled extra-pulmonary disease * Pregnant women * Patients who have greater than 5 pulmonary lesions at the time of study enrollment * Patients who have disease progression outside the lungs within 3 months of enrollment on the study * Disease pathology other than sarcoma subtypes * Patients with a history of metastatic disease from a primary other than sarcoma
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Froedtert Hospital and Medical College of WisconsinMilwaukee, Wisconsin
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 28, 2023. Always confirm current availability with the study team.